A missense variant in complement factor B (CFB) is a potential predictor of 24-week off-treatment response to PegIFNα therapy in Chinese HBeAg-positive chronic hepatitis B patients.

Haitao Chen Jian SunBin ZhouJinxin PengQing XieXieer LiangRong FanCarly ConranJianfeng XuYuan JiXinxin ZhangLi SunJi-Dong JiaGuiqiang WangJin-Lin Hou De-Ke Jiang

Published in: Alimentary pharmacology & therapeutics (2020)

CFB rs12614 is an independent predictor of response to PegIFNα therapy in Chinese HBeAg-positive CHB patients. A PGS integrating CFB rs12614 with STAT4 rs7574865 can effectively discriminate responders to PegIFNα from nonresponders.

Keyphrases

end stage renal disease
hepatitis b virus
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
randomized controlled trial
clinical trial
autism spectrum disorder
climate change
combination therapy